Amerikanische Gesellschaft für Hirudotherapie

Governance Dashboard

How every registry entry is tagged across regulatory status, evidence level, and audience target.

Zuletzt aktualisiert: May 27, 2026Geprüft von: Andrei Dokukin, MD
Editorial transparency \u2014 governance metadataAuto-updates as registries are tagged

Every entry in the ASH registries carries governance metadata: a regulatory status (where the claim sits between FDA-cleared and historical), an evidence level (RCT vs case series vs preclinical), and one or more audience targets (clinician, researcher, patient). This page renders the distribution live, so the editorial state of the knowledge base is visible without having to ask anyone.

Complementary to the Coverage Map (tier-focused) and the Atlas by Organ System (anatomy-focused). The dashboard below counts tags, not interpretations \u2014 buckets labelled "(untagged)" are registry entries that still need governance backfill.

Live registry counts

Pulled from lib/*-registry.ts at render time. Total across all five registries: 792 entries.

Distribution by regulatory status

How each registry breaks down across the seven RegulatoryStatus buckets defined in lib/types/governance.ts. Bar length is relative to the largest bucket within a registry.

Conditions

n = 199
  • FDA-cleared device3
  • Off-label, RCT-supported10
  • Investigational human186

Compounds

n = 201
  • Off-label, RCT-supported9
  • Preclinical / mechanistic192

RCTs

n = 169
  • FDA-cleared device52
  • Off-label, RCT-supported80
  • Investigational human12
  • Preclinical / mechanistic14
  • Historical / educational1
  • Non-clinical science7
  • Not recommended3

Biographies

n = 68
  • Historical / educational37
  • Untagged (governance backlog)31

Jurisdictions

n = 155
  • Non-clinical science105
  • Untagged (governance backlog)50

Distribution by evidence level

GRADE + Oxford CEBM hierarchy. Higher tiers (FDA, systematic review, RCT) at the top of each card; mechanistic and historical at the bottom.

Conditions

n = 199
  • FDA-cleared context3
  • Systematic review1
  • RCT7
  • Cohort / case series11
  • Case report165
  • Mechanistic12

Compounds

n = 201
  • FDA-cleared context9
  • Systematic review1
  • Preclinical (in vivo)20
  • In vitro114
  • Mechanistic52
  • Expert consensus5

RCTs

n = 169
  • Systematic review17
  • Meta-analysis5
  • RCT20
  • Guideline5
  • Cohort / case series51
  • Case report33
  • Preclinical (in vivo)15
  • In vitro1
  • Mechanistic9
  • Expert consensus4
  • Insufficient9

Biographies

n = 68
  • Historical37
  • Untagged31

Jurisdictions

n = 155
  • Insufficient105
  • Untagged50

Distribution by audience target

Audience tags are multi-valued: a single entry can be tagged for both clinicians and researchers, in which case it is counted in each bucket. Totals here may therefore exceed the row's n.

Conditions

n = 199
  • Clinician199
  • Researcher186
  • Patient13

Compounds

n = 201
  • Clinician144
  • Researcher201
  • Regulatory1

RCTs

n = 169
  • Clinician138
  • Researcher168
  • Patient2
  • Institution9
  • Regulatory6

Biographies

n = 68
  • Researcher37
  • Mixed37
  • Untagged31

Jurisdictions

n = 155
  • Institution105
  • Regulatory105
  • Untagged50

Related transparency views

Each of the views below answers a different question about the same underlying registries. Together they form ASH's public editorial dashboard.

  • Coverage Map \u2014 tier-focused view: how many conditions sit at Tier A (FDA-cleared), Tier B (off-label, RCT-supported), Tier C (investigational).
  • Atlas by Organ System \u2014 anatomy-focused view: every condition organised across twelve organ-system categories.
  • PMID Audit Status \u2014 citation-integrity view: which PMIDs in hand-built registries have been verified against PubMed.
  • Transparency and Trust \u2014 narrative overview of ASH's editorial commitments, correction policy, and disclosure practices.

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Governance Dashboard — ASH | Amerikanische Gesellschaft für Hirudotherapie